Entrada Therapeutics Inc

1. 1

   Election of Class II Directors

   ManagementBoard: FOR

   Elect two Class II directors—Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D.—each to serve three-year terms expiring in 2029.

2. 2

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of Ernst & Young LLP as Entrada’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Approve Amendment No. 1 to the Company’s 2021 Stock Option and Incentive Plan

   ManagementBoard: FOR

   Approve Amendment No. 1 to the 2021 Stock Option and Incentive Plan to modify the evergreen provision so that outstanding pre-funded warrants are treated as Outstanding Shares for purposes of calculating the annual automatic increase in the plan reserve.

   More detail

   This management proposal asks shareholders to approve Amendment No. 1 to the Company’s 2021 Stock Option and Incentive Plan to change the plan’s evergreen formula so that ‘‘Outstanding Shares’’ includes shares issued and outstanding plus shares issuable upon exercise of outstanding pre-funded warrants. Management seeks shareholder approval because the Company issued pre-funded warrants in a June 2024 registered direct offering, which raised cash without increasing the count of issued-and-outstanding common shares; as a result, the existing evergreen formula (which only counts issued-and-outstanding shares) produced a smaller annual increase to the share reserve than management believes is economically appropriate. The amendment is prospective and will affect the calculation of future annual increases (January 1, 2027–January 1, 2031), not retroactive awards. The board and compensation committee, supported by an independent consultant, frame this change as necessary to preserve the Company’s ability to grant competitive equity awards for recruiting and retention and to maintain a share pool comparable to peers that did not issue pre-funded warrants. They provide an illustrative example showing the amendment would increase the reserve by roughly 1.69 million additional shares (approximately 4.00% of total capitalization in their example) in the next annual adjustment. Potential shareholder concerns include incremental dilution over time, increased potential future share issuance that could depress per-share metrics, and the governance implication of expanding an equity reserve without new authorized shares; management argues the amendment merely changes the basis for the annual formula and that grants remain subject to administrator discretion and board oversight. The proposal also explains that if shareholders do not approve the amendment, the Company may need to rely more on cash incentives or alternative compensation structures that management believes are less effective at aligning employee interests with shareholders. From a sophisticated investor perspective, key evaluation points include the reasonableness of the magnitude of the additional reserve relative to expected hiring and grant practices, the transparency of how additional shares would be utilized, the expected timeline for usage, and whether the change preserves Section 162(m)/409A/other tax/qualification considerations; the Company states the amendment was developed with consultant input and is compatible with plan governance and Nasdaq rules, and the effective term of future increases would run through plan expiration in October 2031.

4. 4

   Approve Amendment No. 1 to the Company’s 2021 Employee Stock Purchase Plan (ESPP

   ManagementBoard: FOR

   Approve Amendment No. 1 to the 2021 Employee Stock Purchase Plan to modify its evergreen provision so that outstanding pre-funded warrants are included in the definition of Outstanding Shares for the annual increase calculation.

   More detail

   This proposal requests shareholder approval to amend the ESPP’s evergreen mechanism so that the plan’s annual reserve increase considers Outstanding Shares, defined to include shares issued and outstanding plus shares issuable upon exercise of outstanding pre-funded warrants. Management’s motivation mirrors the stock plan amendment: because the Company issued pre-funded warrants in the June 2024 registered direct offering, the numeric base used for the ESPP’s annual 1% increase did not reflect those economic interests, reducing the plan’s automatic replenishment; management contends that including the pre-funded warrants will maintain the annual number of shares available for employee purchase and preserve the ESPP as an effective employee benefit. The amendment affects only future annual increases (through January 1, 2031) and is designed to maintain comparable ESPP capacity versus peers and to support recruitment and retention. Critical shareholder considerations include the dilutive impact of increasing the ESPP reserve over time, the potential cumulative size of the ESPP pool if warrants are exercised, and the balance between maintaining employee benefits and shareholder dilution. The Company indicates consultant input and board oversight informed the proposal and that existing ESPP limits (e.g., $25,000 annual purchase limitation per employee under Section 423) and plan administration constrain potential excesses. For a sophisticated analyst, assessing the proposal requires reviewing the magnitude of expected ESPP usage relative to the incremental shares attributable to the amendment, understanding gating and governance controls around awards, and weighing employee retention benefits versus longer-term dilution and financial statement impacts.

Upcoming shareholder meetings at Entrada Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Entrada Therapeutics Inc 2026 annual meeting?

Entrada Therapeutics Inc (TRDA) holds its 2026 annual shareholder meeting on Wednesday, June 10, 2026.

What is the record date for the Entrada Therapeutics Inc 2026 meeting?

The record date for the Entrada Therapeutics Inc 2026 meeting is Monday, April 13, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Entrada Therapeutics Inc's 2026 meeting?

The board is presenting 2 director nominees at the Entrada Therapeutics Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Entrada Therapeutics Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Entrada Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.